Search Login Register

darifenacin Summary

Description: RN refers to (S),alpha,alpha-isomer; structure given in first source; Enablex transferred from Pfizer to Novartis 2003; muscarinic M(3) receptor antagonist that is indicated for use in treatment of overactive bladder disorder

Also Known As: (S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; Emselex; Enablex; UK-88525; darifenacin hydrochloride Show All >>

Networked: 79 relevant articles (10 outcomes, 22 trials/studies) for this Drug

Key Diseases for which darifenacin is Relevant

  1. Overactive Urinary Bladder (Overactive Bladder) : 7 outcomes 18 studies in 57 results
  2. Urinary Incontinence : 1 outcome 1 study in 2 results
  3. Nocturia : 1 outcome in 2 results
  4. Irritable Bowel Syndrome (Syndrome, Irritable Bowel) : 1 outcome in 1 result
  5. Diarrhea : 1 outcome in 1 result
Show All >>

Drugs Related to darifenacin

  1. tolterodine (Detrol)
  2. oxybutynin (Tavor)
  3. quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)
  4. Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
  5. Muscarinic Antagonists
  6. trospium chloride (Ceris)
  7. propiverine
  8. fesoterodine
  9. Atropine (Hyoscyamine)
  10. Pirenzepine
Show All >>

Therapies Related to darifenacin

  1. Transplants (Transplant)
  2. Injections
  3. Drug Therapy (Chemotherapy)
  4. Castration

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.